{"a":[{"_":"J&J’s bispecific combo slashes myeloma progression risk by 89% in phase 3 trial","$":{"href":"/pharma/jj-bispecific-combo-slashes-myeloma-progression-risk-89-phase-3-trial","hreflang":"en"}}]}
Phase 3positivedual bispecific combinationPositive
AI Analysis
Summary
Johnson & Johnson announced positive Phase 3 data for its dual bispecific antibody combination in earlier-line multiple myeloma, demonstrating an 89% reduction in disease progression risk. The results position the off-the-shelf T-cell engager approach competitively against personalized CAR-T therapies.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
89% reduction in myeloma progression risk
Importance:8/10
Sentiment:
0.85
multiple myelomabispecific antibodyT-cell engagerPhase 3survival data
Related Companies
Read the original article
Published by FiercePharma on July 22, 2026 11:22 PM